'Cancer Compromised My Immune System'
Inbox
| x |
|
4:33 AM (10 hours ago)
|
| |||
Wednesday, April 15, 2020
Tuesday, April 14, 2020
MPR and its specialty editions are circulated to more than 340,000 healthcare professionals. With a reach of over 1.5 million within the Haymarket Medical Network, the MPR website (www.eMPR.com) is utilized by over 530,000 unique visitors a month and generates 1.3 million page views. The MPR App has been downloaded more than 375,000 times and generates more than 750,000 page views a month.
| • Case studies |
| • Clinical charts |
| • Drug updates |
| • Interactive quizzes |
Monday, April 13, 2020
MPR is a multispecialty drug information resource for healthcare professionals offering concise prescribing information,
MPR and its specialty editions are circulated to more than 340,000 healthcare professionals. With a reach of over 1.5 million within the Haymarket Medical Network, the MPR website (www.eMPR.com) is utilized by over 530,000 unique visitors a month and generates 1.3 million page views. The MPR App has been downloaded more than 375,000 times and generates more than 750,000 page views a month.
FDA OKs Blood Purification System for COVID-19 Patients Admitted to ICU
The Food and Drug Administration (FDA) has issued an Emergency Use Authorization to Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge (Terumo BCT Inc. and Marker Therapeutics AG) for the treatment of patients 18 years of age or older with confirmed coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure to reduce proinflammatory cytokines levels.Cytokine levels are typically elevated during infections and can be associated with a cytokine storm in some COVID-19 patients. The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity.
The Spectra Optia Apheresis System is a blood purification system that operates in conjunction with Depuro D2000 Adsorption Cartridge devices. The authorized product uses continuous flow centrifugation and optical detection technology to separate plasma from whole blood, removing cytokines and other inflammatory mediators, and returning the filtered blood to the patient. Plasma filtration may be run for up to 4 hours and may be repeated as needed.
“With today’s authorization of a blood purification device, we are expediting the availability of a treatment option for patients in the ICU to help reduce the severity of the disease,” said FDA Commissioner Stephen M. Hahn, MD. “Our staff will continue our around the clock review of all medical products to expedite the availability of treatments to help fight this devastating disease.”
For more information visit fda.gov.
Convalescent Plasma Treatment Promising in Severe COVID-19
Convalescent Plasma Treatment Promising in Severe COVID-19
Convalescent Plasma Treatment Promising in Severe COVID-19
Kai Duan, from the China National Biotec Group Company Limited in Beijing, and colleagues prospectively enrolled 10 patients with severe COVID-19 confirmed by real-time viral RNA tests. Patients received a transfusion of one dose of CP derived from recently recovered donors with neutralizing antibody titers above 1:640; patients also received maximal supportive care and antiviral agents. From onset of illness to CP transfusion, there was a median time of 16.5 days.
The researchers found that the level of neutralizing antibody increased rapidly up to 1:640 in 5 cases after CP transfusion; in 4 other cases, the high level was maintained (1:640). Significant improvement was seen in clinical symptoms, with an increase of oxyhemoglobin saturation within 3 days. Compared with pretransfusion, several parameters tended to improve, including increased lymphocyte counts and reduction in C-reactive protein. Varying degrees of absorption of lung lesions were seen within seven days on radiological examinations. In seven of the patients who had previous viremia, the viral load was undetectable after transfusion.
“The optimal dose and treatment time point, as well as the definite clinical benefits of CP therapy, need to be further investigated in randomized clinical studies,” the authors write.
Abstract/Full Text
Subscribe to:
Posts (Atom)